PDCD1 and rectal cancer: The initial case report showed that two dMMR locally advanced rectal cancer (LARC) patients received PD-1 inhibitors (nivolumab) monotherapy to avoid adverse events (AEs) of chemoradiotherapy, which also enabled them to achieve pCR and clinical complete remission, and the latter adopted the observation and waiting (W&W) strategy without surgery (58).